Type 2 Diabetes Research
Type 2 diabetes is characterized by insulin resistance and progressive β-cell dysfunction. Incretin-axis agonists are the largest commercial pharmaceutical category of the 2020s in T2D, with GLP-3 (GLP-3 prescription analog, GLP-3 prescription analog), GLP-2 (GLP-2 prescription analog), and GLP-1 (investigational) representing successive generations of receptor pharmacology.
